Western University

Scholarship@Western
Medical Biophysics Publications

Medical Biophysics Department

1-1-2019

The Canadian Dementia Imaging Protocol: Harmonization validity
for morphometry measurements
Olivier Potvin
Institut Universitaire en Santé Mentale de Québec

Isabelle Chouinard
Institut Universitaire en Santé Mentale de Québec

Louis Dieumegarde
Institut Universitaire en Santé Mentale de Québec

Robert Bartha
Robarts Research Institute

Pierre Bellec
University of Montreal

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/biophysicspub
Part of the Medical Biophysics Commons

Citation of this paper:
Potvin, Olivier; Chouinard, Isabelle; Dieumegarde, Louis; Bartha, Robert; Bellec, Pierre; Collins, D. Louis;
Descoteaux, Maxime; Hoge, Rick; Ramirez, Joel; Scott, Christopher J.M.; Smith, Eric E.; Strother, Stephen
C.; Black, Sandra E.; and Duchesne, Simon, "The Canadian Dementia Imaging Protocol: Harmonization
validity for morphometry measurements" (2019). Medical Biophysics Publications. 410.
https://ir.lib.uwo.ca/biophysicspub/410

Authors
Olivier Potvin, Isabelle Chouinard, Louis Dieumegarde, Robert Bartha, Pierre Bellec, D. Louis Collins,
Maxime Descoteaux, Rick Hoge, Joel Ramirez, Christopher J.M. Scott, Eric E. Smith, Stephen C. Strother,
Sandra E. Black, and Simon Duchesne

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/biophysicspub/410

NeuroImage: Clinical 24 (2019) 101943

Contents lists available at ScienceDirect

NeuroImage: Clinical
journal homepage: www.elsevier.com/locate/ynicl

The Canadian Dementia Imaging Protocol: Harmonization validity for
morphometry measurements

T

Olivier Potvina, Isabelle Chouinarda, Louis Dieumegardea, Robert Barthac, Pierre Bellecd,
D. Louis Collinse, Maxime Descoteauxf, Rick Hogee, Joel Ramirezg, Christopher J.M. Scottg,
⁎
Eric E. Smithh, Stephen C. Strotheri, Sandra E. Blackg, Simon Duchesnea,b, , the CIMA-Q group1,
the CCNA group
a

CERVO Research Center, Institut universitaire en santé mentale de Québec, Québec, Canada
Département de radiologie et de médecine nucléaire, Université Laval, Québec, Canada
Robarts Research Institute, Medical Biophysics, Western University, London, Canada
d
Département de psychologie, Université de Montréal, Montréal, Québec, Canada
e
McConnell Brain imaging Center, Montreal Neurological Institute, McGill University, Montréal, Canada
f
Université de Sherbrooke, Sherbrooke, Québec, Canada
g
LC Campbell Cognitive Neurology Research, Sunnybrook Research Institute, University of Toronto, Toronto, Canada
h
Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Canada
i
Rotman Research Institute, Baycrest Medical Biophysics, University of Toronto, Toronto, Canada
b
c

A R T I C LE I N FO

A B S T R A C T

Keywords:
Neuroimaging
Magnetic resonance imaging
Standardization
Morphometry
Multi-centric studies

The harmonized Canadian Dementia Imaging Protocol (CDIP) has been developed to suit the needs of a number
of co-occurring Canadian studies collecting data on brain changes across adulthood and neurodegeneration. In
this study, we verify the impact of CDIP parameters compliance on total brain volume variance using 86 scans of
the same individual acquired on various scanners. Data included planned data collection acquired within the
Consortium pour l'identiﬁcation précoce de la maladie Alzheimer - Québec (CIMA-Q) and Canadian Consortium
on Neurodegeneration in Aging (CCNA) studies, as well as opportunistic data collection from various protocols.
For images acquired from Philips scanners, lower variance in brain volumes were observed when the stated CDIP
resolution was set. For images acquired from GE scanners, lower variance in brain volumes were noticed when
TE/TR values were within 5% of the CDIP protocol, compared to values farther from that criteria. Together,
these results suggest that a harmonized protocol like the CDIP may help to reduce neuromorphometric measurement variability in multi-centric studies.

1. Introduction
Quantitative methods to extract speciﬁc and sensitive biomarkers
from neuroimages (e.g. algorithms, software)(Frisoni et al., 2013) can
be shared to ensure that similar post-acquisition processing is performed in a standardized fashion. However, there will be a large variance in the data from laboratory to laboratory if one does not standardize beforehand the process of acquiring the imaging data. This is
especially true of longitudinal, multi-centric settings where the wide
array of models and vendors, on top of conﬁguration changes

throughout the life cycle of these scanners, signiﬁcantly aﬀects performance and data quality.
To counteract these eﬀects, several initiatives have developed
standard operating procedures to minimize variability in neuroimage
acquisition. Within the context of aging and neurodegeneration, one of
the most well-known of such eﬀorts was advanced by the Alzheimer's
Disease Neuroimaging Initiative (ADNI)(www.adni-info.org). It has
proposed comprehensive cognitive, behavioural, and especially neuroimaging procedures that have been harmonized and implemented
across > 55 sites in Canada and the U.S. (Jack Jr. et al., 2008).
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Table 1
Characteristics of scans.
Site
CDIP acquisitions
CAMH
Hamilton
PERFORM
Seaman
WCMI
CHUM
CHUS
IRM Quebec

UBC
BIC
SickKids
IUGM

IUSMD
Ottawa
Peter S. Allen
Queens
Robarts
RUH
St. Michael's
Sunnybrook
York
CDIP total

Vendor

Model

Resolution (mm3)

TE (msec)

TR (msec)

Flip angle

TI (msec)

Plane

Number of scans

GE
GE
GE
GE
GE
GE
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Philips
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens
Siemens

DISCOVERY MR750
DISCOVERY MR750
DISCOVERY MR750
DISCOVERY MR750
DISCOVERY MR750
SIGNA Pioneer
Achieva
Ingenia
Ingenia
Ingenia
Achieva
Achieva
Achieva
Achieva
Achieva
Achieva
Achieva
Intera
Intera
TrioTim
Prismaﬁt
Prismaﬁt
TrioTim
Prismaﬁt
Prismaﬁt
TrioTim
Prismaﬁt
TrioTim
Prisma
TrioTim
Prismaﬁt
Skyra
Skyra
Prisma
Prismaﬁt

1.00
1.00
1.00
1.00
1.00
0.88
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

2.94
3.18
2.98
3.08
3.05
3.16
3.30
3.35
3.30
3.33
3.14
3.33
3.31
3.36
3.34
3.35
3.30
3.28
3.27
2.98
2.96
2.98
2.98
2.96
2.98
2.98
2.98
2.98
2.98
1.97
2.98
2.98
2.98
2.98
2.98

6.7
8.2
6.9
7.5
7.4
7.4
7.3
7.3
7.3
7.3
6.9
7.3
7.3
7.4
7.4
7.4
7.3
7.3
7.2
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0
2300.0

11
11
11
11
11
12
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9

400
400
400
400
400
450
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
900
900
900
900
900
900
900
900
900
900
900
900
900
900
900
900

Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal

1
1
2⁎
1
2
2
2
1
3
1
1
2
2
2
1
1
1
1
1
7
3
1
7
4
2
5
1
1
2
1
2
2
1
1
1
69

Ingenia CX
Ingenia CX
Achieva
Achieva
Achieva
Achieva
Achieva
Achieva
Prisma
Prisma
Skyra
Skyra

1.00
0.22
0.48
0.48
1.00
0.69
0.48
1.00
1.00
0.58
1.00
0.58

3.30
5.57
na
na
3.13
na
na
3.14
2.98
3.08
2.96
3.08

7.3
11.8
na
na
6.9
na
na
6.9
2300.0
2300.0
2300.0
2300.0

9
8
na
na
8
na
na
8
9
9
9
9

ns
ns
ns
ns
ns
ns
ns
ns
900
900
900
900

Sagittal
Sagittal
Sagittal
Axial
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal
Sagittal

1
2
2
1
2
1
1
2
1
2
1
1
17

Non-CDIP acquisitions
Philips
Philips
Philips
IRM Quebec
Philips
Philips
Philips
Philips
Philips
Philips
Siemens
Siemens
Siemens
Siemens
Siemens
Non-CDIP total

BIC: McConnell Brain Imaging Centre. CAMH: The Centre for Addiction and Mental Health. CHUM: Centre hospitalier universitaire de Montreal. CHUS: Centre
hospitalier universitaire de Sherbrooke. IUSMD: Brain Imaging Center of the Institut universitaire en santé mentale Douglas. Hamilton: St-Joseph's Healthcare
Hamilton. SickKids: Hospital for Sick Children. IUGM: Institut universitaire de gériatrie de Montréal. Ottawa: The Ottawa Hospital Civic. PERFORM: Concordia
University Perform Centre. Peter S. Allen: Peter S. Allen MR Research Centre. Queens: Queens University. Robarts: Robarts Research Institute. RUH: Royal University
Hospital. Seaman: Seaman Family MR Research Centre. St. Michael's: St. Michael's Hospital. Sunnybrook: Sunnybrook Research Institute. ns: Not speciﬁed. TE: Echo
time. TI: Inversion time. TR: Repetition time. UBC: University of British Colombia. WCMI: West Coast Medical Imaging – Uptown. York: York MRI Facility. ⁎One scan
resolution is actually 0.999 mm3.

sequences were harmonized across three MRI vendors, namely General
Electric Healthcare (GE), Phillips Medical Systems (Philips), and Siemens Healthcare (Siemens). Sites are said to be CDIP-compliant when
they follow a three-step process, namely qualiﬁcation of the protocol,
on-going quality control using geometric and human phantom scans,
and on-going quality assurance during the study.
Yet while harmonization might be appealing in principle, the demonstration of its usefulness remains to be completed. Limited data
exists on the pre/post advantages of harmonizing acquisition parameters. This study clariﬁes some of this uncertainty by assessing the
eﬀect of deviation from compliance to the CDIP T1w MRI protocol on

In Canada, a collection of studies centered on dementias started
acquiring data in the 2013–2016 timeframe and needed a common,
harmonized process for magnetic resonance imaging (MRI) data acquisition that went beyond the ADNI standard of the time. Thus, a
group of physicists, physicians and research coordinators developed
what is referred to as the Canadian Dementia Imaging Protocol (CDIP;
www.cdip-pcid.ca)(Duchesne et al., 2019). The CDIP includes the following sequences: (a) an isotropic high-resolution 3D T1-weighted
(T1w) MRI; (b) an interleaved PD/T2-weighted MRI; (c) T2* and FLAIR
MRIs; (d) a 30+ directions diﬀusion MRI; and (e) a functional connectivity, resting-state BOLD MRI. Parameters for each one of these
2
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Hospital for Sick Children (Toronto, Canada), the Unité de Neuroimagerie Fonctionnelle du Centre de recherche de l'Institut universitaire en
gériatrie de Montréal (Montréal, Canada), the Centre Hospitalier Universitaire de Montréal (Montréal, Canada), the Brain Imaging Center of
the Institut universitaire en santé mentale Douglas (Montréal, Canada),
the Ottawa Civic Hospital (Ottawa, Canada), the Peter S. Allen MR
Research Center of the University of Alberta (Edmonton, Canada),
Queen's University (Kingston, Canada), the Robarts Research Institute
at the University of Western Ontario (London, Ontario), the Royal
University Hospital Radiology Department (Saskatoon, Canada), Siemens (Erlangen, Germany), the St. Michael's Hospital (Toronto, Canada), the Radiology Department of Sunnybrook Hospital (Toronto,
Canada), and the York MRI Facility (Toronto, Canada).
The MEDICS Laboratory (CERVO Research Center, Québec, Canada)
was responsible for MRI data acquisition and analysis including coordination, development and implementation of CDIP at each site; site
qualiﬁcation; site quality control via the single volunteer scans; and ongoing quality assurance for the CCNA and CIMA-Q studies.

brain morphometry variance. Deviation from the CDIP was analyzed for
three key parameters (resolution, echo time and repetition time). Our
hypothesis was that increasing compliance to CDIP would lower
variability in morphometric brain measures, outside of the application
of any further speciﬁc image pre/post processing. A secondary objective
was to release publicly for unrestricted usage this unique dataset,
comprising nearly 100 T1w MRI scans of the same individual acquired
on various scanners over the course of a few years.
2. Materials and methods
2.1. Participant
A Single Individual volunteering for Multiple Observations across
the Network (SIMON) took part in this study (SIMON Dataset; http://
fcon_1000.projects.nitrc.org/indi/retro/SIMON.html SIMON is an ambidextrous male aged between 38 and 46 years old across the scans used
in the present study, and was free from known cognitive impairment,
neurological disease or psychiatric disorders. The volunteer provided
informed consent for all participating studies as well as the release of
the MR data.

2.4. Image acquisition and processing
For the present study, 86 SIMON scans (nine on GE, 31 on Philips,
and 46 on Siemens) were acquired on 28 diﬀerent 3-Tesla units (10
diﬀerent models) over the course of eight years from 2009 to 2018
(Table 1). Twenty of these diﬀerent scanners had more than one scan
and most were follow-up scans (64/86) with a mean scan interval of
238 days and a range between 0 and 873 days (GE: 448, 0–823; Philips:
251, 0–873; Siemens: 197, 0–595). The majority (69/86) of these scans
were acquired for the CCNA and CIMA-Q studies during development
and implementation of the protocol.
The CDIP (www.cdip-pcid.ca) has been previously described elsewhere in detail (Duchesne et al., 2019). Brieﬂy, the T1w acquisition
sequence is a sagittal 3D isotropic scan with high resolution (voxel
size = 1.0 × 1.0 × 1.0 mm3), an acceleration factor of 2 (Siemens: 3D
MP-RAGE-iPAT: 2; GE: 3D FAST-SPGR-ASSET 2.0; Philips: 3D TFE-Fast
Sense: 2). Parameters for the 3D T1w acquisition were inspired from
work done in the ADNI project (Jack Jr. et al., 2008), resulting in an
isotropic resolution and the use of accelerated imaging. One should
note that even if CDIP calls for precise parameter values, many acquisitions displayed discrepancies with these targets. While this was corrected for future acquisitions (the purpose of having a human phantom
being to test compliance and ensuring quality), it provided us with a
convenience sample of scans with diﬀerent parameters. Reasons for
non-compliance included human initiative, and reduced precision due
to some scanner interfaces not allowing the precise entry and/or import
of set values.
Seventeen scans were acquired through other research projects,
including visits to manufacturers sites (see Table 1 for more details on
parameters). These images form a convenience sample, did not follow
any given protocol nor systematically assessed parameter variability,
but were acquired in the context of research studies and/or manufacturer visits, with an eye towards research studies. Thus, while these
protocols made diﬀerent technical choices, all of them were deemed
suitable for research project purposes, and hence acceptable for our
study.
Brain volumes were extracted from each scan using recon-all pipeline of FreeSurfer 6.0 (http://freesurfer.net) with default parameters.
The total brain volume without the ventricles (brainsegvolnotvent)
from the aseg ﬁle was used.

2.2. Participating studies
Several organizations and projects have contributed to the elaboration of the CDIP protocol and the acquisition of SIMON data,
namely the Canadian Alliance for Healthy Hearts and Minds (Anand et al.,
2016)(cahhm.mcmaster.ca); the Consortium pour l'identiﬁcation précoce
de la maladie d'Alzheimer – Québec (CIMA-Q)(www.cima-q.ca); the O2
study from the Consortium Québécois sur la Découverte du Médicament
(www.cqdm.org); the Medical Imaging Trials Network of Canada – C6
(clinicaltrials.gov/ct2/show/NCT02330510); and the Ontario Brain Institute's Ontario Neurodegenerative Disease Research Initiative (Farhan
et al., 2017)(ondri.ca). CIMA-Q was founded in 2013 with a $2,500,000
grant from the Fonds d'Innovation Pﬁzer - Fond de Recherche Québec –
Santé sur la maladie d'Alzheimer et les maladies apparentées. The main
objective is to build a cohort of participants characterized in terms of
cognition, neuroimaging and clinical outcomes in order to acquire
biological samples allowing 1) to establish early diagnoses of Alzheimer's disease, 2) to provide a well characterized cohort and 3) to
identify new therapeutic targets. The principal investigator and director
of CIMA-Q is Dr. Sylvie Belleville of the Centre de recherche de l'Institut
universitaire de gériatrie de Montréal, CIUSSS Centre-sud-de-l'Île-deMontréal. CIMA-Q represent a common eﬀort of several researchers
from Québec aﬃliated with Université Laval, McGill University, Université de Montréal, and Université de Sherbrooke. CIMA-Q recruited
350 cognitively healthy participants, with subjective cognitive impairment, mild cognitive impairment, or Alzheimer's disease, between 2013
and 2016.
2.3. Participating centers
Most scans were acquired as part of three projects, namely the
CIMA-Q, the Canadian Consortium for Neurodegeneration of Aging
(CCNA), and courtesy scans at MR manufacturers. Scans were thus
obtained at 23 diﬀerent sites (see also Table 1): The Centre for Addiction and Mental Health (Toronto, Canada), St-Joseph's Healthcare Hamilton (Hamilton, Canada), the MRI unit of the PERFORM Center of
Concordia University (Montréal, Canada), the Seaman MRI Center of
the University of Calgary (Calgary, Canada), West Coast Medical Imaging – Uptown, the Centre hospitalier universitaire de Montréal
(Montréal, Canada), the Centre d'Imagerie Moléculaire de Sherbrooke
of the Centre Hospitalier Universitaire de Sherbrooke (Sherbrooke,
Canada), Philips (Best, Netherlands), IRM Québec (Québec, Canada),
University of British Colombia (Vancouver, Canada), the Brain Imaging
Center of the Montreal Neurological Institute (Montréal, Canada), the

2.5. Statistical analyses
To verify whether following CDIP parameters reduced morphometric measures variability, we categorized scans based on their parameters (resolution, echo time (TE), repetition time (TR)) in a cumulative fashion of being increasingly compliant with the CDIP protocol:
3
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CDIP (scans acquired with parameters within 1% of CDIP values);
CDIP ± 5% (all scans within 5% of CDIP values); CDIP ± 10% (all scans
within 10% of CDIP values); and Any criteria (all scans). For GE and
Philips vendors, TR represents the inner loop gradient echo TR, whereas
for Siemens it represents the magnetization-prepared rapid gradientecho (MPRAGE) outer loop TR. Thus, we planned to analyze GE/Philips
and Siemens results separately. To compare variance across these categories, p values between categories were calculated based on conﬁdence intervals (95%) computed from bootstrapping with 1000
random sampling with replacement. Moreover, to verify the eﬀect of
protocol on morphometric measures, we used linear-mixed models with
parameter categories as a between factor (each image being within a
single category), age as covariate and scanner model as a random
factor.
All statistical analyses were conducted in Python using SciPy (Jones
et al., 2001) and StatsModels (Seabold and Perktold, 2010) modules.
Fig. 2. Bar plot showing the median standard deviation of total brain volume
across vendors according to cumulative echo time percentage discrepancy from
the CDIP criteria (GE 1%: 2.87–2.93 ms, 5% 2.75–3.05 ms, 10%: 2.61–3.19 ms;
Philips 1%: 2.75–3.33 ms, 5% 2.83–3.47 ms, 10%: 2.97–3.63 ms; Siemens 1%:
2.95–3.01 ms, 5% 2.83–3.13 ms, 10%: 2.68–3.28 ms). Error bars denote 95%
conﬁdence intervals. White numbers indicate the number of scans meeting each
criterion.

3. Results
3.1. Parameter compliance
For unknown reasons, ﬁve images from Philips scanners had no TE
and TR values in the image headers, and these images were only used
for resolution analyses.
As mentioned earlier in Methods, because of the GE scanner interface and human resources training at the visited sites, speciﬁc parameter values could not be easily transferred between machines. Thus,
even when sites intended to follow the CDIP protocol (9 out of 10
scans), no site matched the aimed CDIP TE value and only one site
matched the intended TR value. Further, due to automatic parameter
deﬁnition, all intended Philips CDIP scans were within 5% of expected
TE and TR values.
3.2. Impact of parameter compliance on morphometric variance value
Figs. 1, 2 and 3 show standard deviations for whole brain volumes
across categories for resolution, TE and TR parameters, respectively.
Resolution: For resolution, the parameter variability was not suﬃcient to allow more than two categories, that is either meeting CDIP
values (1 × 1 × 1 mm3) or not. When all vendors were grouped, the
CDIP resolution variance was not signiﬁcantly lower than the non-CDIP
(p = .0746). Philips vendor results showed signiﬁcant lower variance
(p = .0132) with the CDIP resolution value compared to other values
(note that Philips had the largest range of resolutions of all vendors).
TE: While variance increased in a stepwise fashion for TE across

Fig. 3. Bar plot showing the median standard deviation of total brain volume
for GE and Philips vendors according to cumulative repetition time percentage
discrepancy from the CDIP criteria (GE 1%: 6.63–6.77 ms, 5% 6.37–7.04 ms,
10%: 6.03–7.37 ms, Philips 1%: 7.23–7.37 ms, 5%: 6.94–7.67 ms, 10%:
6.57–8.03 ms). Error bars denote 95% conﬁdence intervals. White numbers
indicate the number of scans meeting each criterion.

categories, there was no statistically signiﬁcant diﬀerence between
categories. The diﬀerence closest to reach signiﬁcance was between
CDIP ± 1% and both CDIP ± 10% (p = .0664) and “any criteria”
(p = .0603) categories. Results for GE images indicated signiﬁcant
lower variance with the CDIP ± 5% compared to the “Any criteria”
(p = .0220) and CDIP ± 10% (p = .0275) categories.
TR: Since there was no variance of TR for Siemens, analyses and
Fig. 3 concern only GE and Philips vendors, and thus this study focus on
inner-loop TR variability only. Compared to the CDIP ± 1% category,
higher variance was observed with the “Any criteria” category
(p = .0279). However, this diﬀerence was likely due to the GE vendor
results since no signiﬁcant diﬀerences between categories were observed for Philips (ps > 0.3888) while lower variance with the
CDIP ± 5% compared to the “Any criteria” (p = .0133) categories was
observed for GE.
For Siemens MRIs, while the interfaces allowed some parameters to
be entered directly, the system automatically calculated minimum
achievable TE values. Since we presented each unit with the same
parameter settings, this calculation showed very little variability

Fig. 1. Bar plot showing the median standard deviation of total brain volume
across vendors according to cumulative resolution criteria. Error bars denote
95% conﬁdence intervals. White numbers indicate the number of scans meeting
each criterion.
4
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Fig. 4. Box plot showing the total brain volume across vendors according to resolution criteria. Boxes show the ﬁrst and third quartiles with the line denoting the
median. Whiskers represent the lowest/highest datum still within 1.5 interquartile range (IQR) of the lower/higher quartile.

CDIP ± 5% (2.0%, p = .0047) compared to the ‘Any criteria’ category.
Finally, age had a signiﬁcant eﬀect in the resolution model (p = .0003),
but not in the TE (p = .2094) or TR (p = .6574) models, suggesting that
TE and TR variations were responsible for that age eﬀect. Because of the
lack of parameters variability within each vendor leading to small
numbers for many categories, most separated linear mixed models were
not possible. Nonetheless, there was a signiﬁcant eﬀect of resolution for
Siemens images, with CDIP images having smaller brain volumes
(−2.4%, p = .0195).

between categories and all of them had similar resolution, TE, and TR
values.

3.3. Impact of parameter compliance on morphometric mean value
Figs. 4, 5 and 6 display boxplots showing the median and dispersion
of brain volumes across categories for the resolution, TE and TR parameters, respectively. Linear mixed models taking into account age and
scanner model, indicated that when all vendors were pooled together,
the mean brain volumes were not signiﬁcantly diﬀerent between CDIP
and non-CDIP resolution values (p = .0585). On the other hand, TE
CDIP ± 5% category had signiﬁcantly larger brain volumes (1.9%,
p = .0252) compared to the ‘Any criteria’ category and CDIP ± 1% was
also close to signiﬁcance (1.5%, p = .0544). Similarly, for TR (GE and
Philips only), larger brain volumes CDIP ± 1% (1.4%, p = .0368) and

4. Discussion
The harmonized Canadian Dementia Imaging Protocol has been
developed to suit the needs of several co-occurring Canadian studies
collecting data on brain changes across adulthood and

Fig. 5. Box plot showing the total brain volume across vendors according to echo time percentage discrepancy from the CDIP criteria (GE 1%: 2.87–2.93 ms, 5%
2.75–3.05 ms, 10%: 2.61–3.19 ms; Philips 1%: 2.75–3.33 ms, 5% 2.83–3.47 ms, 10%: 2.97–3.63 ms; Siemens 1%: 2.95–3.01 ms, 5% 2.83–3.13 ms, 10%:
2.68–3.28 ms). Boxes show the ﬁrst and third quartiles with the line denoting the median. Whiskers represent the lowest/highest datum still within 1.5 interquartile
range (IQR) of the lower/higher quartile.
5
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Fig. 6. Box plot showing the total brain volume for GE and Philips vendors according to repetition time percentage discrepancy from the CDIP criteria (GE 1%:
6.63–6.77 ms, 5% 6.37–7.04 ms, 10%: 6.03–7.37 ms, Philips 1%: 7.23–7.37 ms, 5%: 6.94–7.67 ms, 10%: 6.57–8.03 ms). Boxes show the ﬁrst and third quartiles with
the line denoting the median. Whiskers represent the lowest/highest datum still within 1.5 interquartile range (IQR) of the lower/higher quartile.

T2*, PD/T2w, FLAIR, diﬀusion and resting state). There have been
other instances of similar data that have been acquired and distributed
to the community, notably: Brown et al. (2011), who tested 18 participants to investigate sources of variation in the blood oxygen leveldependent signal across four MRI sites; Friedman et al. (2008), who
used ﬁve participants to estimate the test-retest and between-site reliability of fMRI assessments across 10 MRI sites; Han et al. (2006), who
scanned 15 healthy older participants four times at three sites; Suckling
et al. (2012) who used 12 participants to carry out a test-retest calibration experiment acquiring functional and structural MRI across three
MRI sites; and Suckling et al. (2014) who scanned six participants in
order to carry out calibration experiments at each of three MRI sites.
Comparatively, our study can contribute a dataset of a single subject,
scanned 86 times on 28 diﬀerent units, which can be useful to answer a
number of methodological questions.

neurodegeneration. In this study, we veriﬁed whether using the CDIP
was beneﬁcial in lowering variability in gross brain size measurement
on a standard post-processing tool, without applying any speciﬁc image
pre/post processing. We used a substantial convenience dataset of a
single individual acquired on 10 scanner models across 86 diﬀerent
sessions, which resulted in many of those not strictly adhering to the
CDIP-depicted parameter values.
First, using the CDIP resolution value (1 × 1 × 1 mm) revealed that
compared to other resolution, the CDIP had lower brain volume variance for Philips scanners. One possible factor in explaining the difference in reproducibility between vendors is the choices made during
post-acquisition reconstruction of images, for example the application
of smoothing/ﬁltering (see Supplementary Fig. 1 for image examples of
each vendor). Customization at this processing level is usually not accessible to investigators. Second, brain volume variance appeared to
increase as deviation from the CDIP TE and TR parameters increased,
but this was signiﬁcant only for GE scanners. Moreover, some mean
eﬀects up to 2% were also observed, notably for the resolution parameter in Siemens scanners, with higher resolution leading to larger
volumes compared to the CDIP resolution.
Overall, these ﬁndings suggest that increasing non-adherence to a
standard protocol, at least for the tested parameters, correspondingly
increases morphological variability in brain measurements at a magnitude on par with that of some pathologies of interest – either in a
transverse or longitudinal setting. They strengthen the argument for
ensuring compliance with a harmonized protocol for multi-centric
studies.
Further, the between-vendor oﬀsets could feed into a next iteration
of the CDIP protocol, in order to change contrast and bring these
measures closer together.

5. Limitations
The main limitation of our study is that the data originates from a
convenience sample, and therefore our acquisitions were not designed
to systematically study parameter variability. In fact, it was rather the
opposite; the implementation of the protocol was an attempt at removing such variability. However, local variations, interface diﬀerences, and a few additional scans – outside of the CDIP project – allowed for the comparisons being presented. In truth, variability mainly
diﬀered between vendors due to interface design choices. Sequence
implementation choices for some vendors (e.g. Philips, GE) restrict the
number of parameters that can be ﬁxed by the user, letting the system
automatically calculate values, whereas other manufacturers will allow
the complete speciﬁcation – and therefore transfer – of parameter values from one scanner to another (e.g. Siemens), therefore increasing
conformity to a given protocol. One should note that Siemens
Healthcare platform is well represented in the Canadian research
landscape, it forms the bulk of the images under consideration while the
number of GE units is more limited in Canada, resulting in a lower
number of images (n = 9). Therefore, conclusions regarding GE scanners should be interpreted with caution. Most of our development took
place on Philips Medical System scanners, and hence we had the most
variability across resolution, TE and TR values for this platform and
thus, the strongest conclusions should be drawn for this subsample.

4.1. Strengths
One strength of our study is the use of a unique dataset comprising
86 scans of a single individual across multiple scanner models, vendors,
and sites. To assess variability across sites in multi-centric studies, such
data are required and are relatively rare. The availability of such data
across sites and vendors is of paramount importance to the ﬁeld of
image processing. As such, the CDIP group intends to make public all
MRI data acquired of SIMON, including all other CDIP contrasts (e.g.
6
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The ideal study would need to compare systematic variations of
CDIP parameters. However, such systematic parameters variations
would be hard to conduct in a single human subject, especially in a
multi-centric context since the same number of scans for each parameters combination would need to be evaluated for each site, yielding a
very high number of scans. However, using animals, this type of study
could be feasible. For example, a non-human primate could be anaesthetized and scanned with multiple systematic parameters variations,
which required to run the sequences multiple times and requires much
more time. However, even with this procedure, the logistic of traveling
with a live animal, especially in our case (across Canada), would pose
other challenges.
Moreover, since our objective was to assess whether the use of the
CDIP would be beneﬁcial in lowering the variability in morphometric
measures of the brain before applying any speciﬁc image pre/post
processing, we used the FreeSurfer cross-sectional default pipeline to
process the images. Thus, we did not aim at maximizing the reliability
and other pipelines might yield diﬀerent variability measurements.
Other steps can be done to further minimize variability across sites such
as image denoising, registration and distortion correction using geometric phantoms; and in the case of longitudinal data, constrained registration. The use of diﬀerent pipelines and the impact of these techniques however, extended beyond the scope of this study.
Finally, when comparing images from diﬀerent manufacturers, one
needs to be aware of diﬀerences in parameters that may at ﬁrst pass
seem identical. For example, the deﬁnition of “sagittal acquisition” is
potentially ambiguous, given that there is no real ‘slice select’ direction
for acquisition but 2 phase-encoding directions instead, either of which
could represent the nominal ‘slice’ direction (and therefore deﬁne the
nominal orientation). This is important because it will inﬂuence the 3D
voxel point spread function, and therefore potentially aﬀect the volumetric measurements reported in the manuscript, as well as determining the direction of motion artifacts (e.g. from eye movement).

References
Anand, S.S., Tu, J.V., Awadalla, P., Black, S., Boileau, C., Busseuil, D., Desai, D., Despres,
J.P., de Souza, R.J., Dummer, T., Jacquemont, S., Knoppers, B., Larose, E., Lear, S.A.,
Marcotte, F., Moody, A.R., Parker, L., Poirier, P., Robson, P.J., Smith, E.E., Spinelli,
J.J., Tardif, J.C., Teo, K.K., Tusevljak, N., Friedrich, M.G., Investigators, C.S, 2016.
Rationale, design, and methods for Canadian alliance for healthy hearts and minds
cohort study (CAHHM) - a Pan Canadian cohort study. BMC Public Health 16, 650.
Brown, G.G., Mathalon, D.H., Stern, H., Ford, J., Mueller, B., Greve, D.N., McCarthy, G.,
Voyvodic, J., Glover, G., Diaz, M., Yetter, E., Ozyurt, I.B., Jorgensen, K.W., Wible,
C.G., Turner, J.A., Thompson, W.K., Potkin, S.G., Function Biomedical Informatics
Research, N, 2011. Multisite reliability of cognitive BOLD data. NeuroImage 54,
2163–2175.
Duchesne, S., Chouinard, I., Potvin, O., Fonov, V.S., Khademi, A., Bartha, R., Bellec, P.,
Collins, D.L., Descoteaux, M., Hoge, R., McCreary, C.R., Ramirez, J., Scott, C.J.M.,
Smith, E.E., Strother, S.C., Black, S.E., CIMA-Q group and the CCNA group, 2019. The
Canadian Dementia Imaging Protocol: harmonizing national cohorts. J. Magn. Reson.
Imaging 49, 456–465.
Farhan, S.M., Bartha, R., Black, S.E., Corbett, D., Finger, E., Freedman, M., Greenberg, B.,
Grimes, D.A., Hegele, R.A., Hudson, C., Kleinstiver, P.W., Lang, A.E., Masellis, M.,
McIlroy, W.E., McLaughlin, P.M., Montero-Odasso, M., Munoz, D.G., Munoz, D.P.,
Strother, S., Swartz, R.H., Symons, S., Tartaglia, M.C., Zinman, L., Investigators, O.,
Strong, M.J., 2017. The Ontario neurodegenerative disease research initiative
(ONDRI). Can. J. Neurol. Sci. 44, 196–202.
Friedman, L., Stern, H., Brown, G.G., Mathalon, D.H., Turner, J., Glover, G.H., Gollub,
R.L., Lauriello, J., Lim, K.O., Cannon, T., Greve, D.N., Bockholt, H.J., Belger, A.,
Mueller, B., Doty, M.J., He, J., Wells, W., Smyth, P., Pieper, S., Kim, S., Kubicki, M.,
Vangel, M., Potkin, S.G., 2008. Test-retest and between-site reliability in a multicenter fMRI study. Hum. Brain Mapp. 29, 958–972.
Frisoni, G.B., Bocchetta, M., Chetelat, G., Rabinovici, G.D., de Leon, M.J., Kaye, J.,
Reiman, E.M., Scheltens, P., Barkhof, F., Black, S.E., Brooks, D.J., Carrillo, M.C., Fox,
N.C., Herholz, K., Nordberg, A., Jack Jr., C.R., Jagust, W.J., Johnson, K.A., Rowe,
C.C., Sperling, R.A., Thies, W., Wahlund, L.O., Weiner, M.W., Pasqualetti, P., Decarli,
C., ISTAART's NeuroImaging Professional Interest Area, 2013. Imaging markers for
Alzheimer disease: which vs how. Neurology 81, 487–500.
Han, X., Jovicich, J., Salat, D., van der Kouwe, A., Quinn, B., Czanner, S., Busa, E.,
Pacheco, J., Albert, M., Killiany, R., Maguire, P., Rosas, D., Makris, N., Dale, A.,
Dickerson, B., Fischl, B., 2006. Reliability of MRI-derived measurements of human
cerebral cortical thickness: the eﬀects of ﬁeld strength, scanner upgrade and manufacturer. NeuroImage 32, 180–194.
Jack Jr., C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D.,
Borowski, B., Britson, P.J., Whitwell, J.L., Ward, C., Dale, A.M., Felmlee, J.P., Gunter,
J.L., Hill, D.L., Killiany, R., Schuﬀ, N., Fox-Bosetti, S., Lin, C., Studholme, C., DeCarli,
C.S., Krueger, G., Ward, H.A., Metzger, G.J., Scott, K.T., Mallozzi, R., Blezek, D., Levy,
J., Debbins, J.P., Fleisher, A.S., Albert, M., Green, R., Bartzokis, G., Glover, G.,
Mugler, J., Weiner, M.W., 2008. The Alzheimer's disease neuroimaging initiative
(ADNI): MRI methods. J. Magn. Reson. Imaging 27, 685–691.
Jones, E., Oliphant, T., Peterson, P., 2001. SciPy: Open Source Scientiﬁc Tools for Python.
Seabold, S., Perktold, J., 2010. Statsmodels: econometric and statistical modeling with
python. In: Proceedings of the 9th Python in Science Conference.
Suckling, J., Barnes, A., Job, D., Brennan, D., Lymer, K., Dazzan, P., Marques, T.R.,
MacKay, C., McKie, S., Williams, S.R., Williams, S.C., Deakin, B., Lawrie, S., 2012.
The neuro/PsyGRID calibration experiment: identifying sources of variance and bias
in multicenter MRI studies. Hum. Brain Mapp. 33, 373–386.
Suckling, J., Henty, J., Ecker, C., Deoni, S.C., Lombardo, M.V., Baron-Cohen, S., Jezzard,
P., Barnes, A., Chakrabarti, B., Ooi, C., Lai, M.C., Williams, S.C., Murphy, D.G.,
Bullmore, E., Consortium, M.A., 2014. Are power calculations useful? A multicentre
neuroimaging study. Hum. Brain Mapp. 35, 3569–3577.

6. Conclusions
The results of the present study suggest that a harmonized protocol
like the CDIP may help to reduce variability in neuromorphometric
measures for multi-centric studies, but further studies with systematic
parameters variation are needed to draw ﬁrmer conclusions. The dataset used in this article is available on the International Neuroimaging
Data-Sharing initiative platform (INDI; http://fcon_1000.projects.nitrc.
org/indi/retro/SIMON.html).
Supplementary data to this article can be found online at https://
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